What is HC Wainwright’s Estimate for Evolus FY2026 Earnings?

Evolus, Inc. (NASDAQ:EOLS) – Equities researchers at HC Wainwright dropped their FY2026 earnings per share (EPS) estimates for shares of Evolus in a research report issued to clients and investors on Monday, March 30th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of ($0.22) for the year, down from their prior forecast of ($0.17). HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for Evolus’ current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for Evolus’ FY2027 earnings at $0.19 EPS, FY2028 earnings at $0.64 EPS, FY2029 earnings at $1.04 EPS and FY2030 earnings at $1.41 EPS.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported $0.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.09). The firm had revenue of $90.30 million during the quarter, compared to analyst estimates of $89.58 million.

Several other analysts also recently commented on the stock. Needham & Company LLC reissued a “hold” rating on shares of Evolus in a research report on Wednesday, December 24th. Stifel Nicolaus reduced their price objective on shares of Evolus from $20.00 to $17.00 and set a “buy” rating for the company in a research note on Tuesday, January 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Evolus in a report on Monday, December 22nd. BTIG Research reissued a “buy” rating and set a $13.00 target price on shares of Evolus in a research report on Wednesday, March 4th. Finally, Wall Street Zen lowered Evolus from a “buy” rating to a “hold” rating in a report on Sunday, March 15th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Evolus presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Evolus Stock Performance

Shares of EOLS opened at $4.31 on Wednesday. The firm has a market cap of $280.41 million, a PE ratio of -5.32 and a beta of 1.00. The firm’s 50 day moving average price is $4.64 and its 200 day moving average price is $5.87. Evolus has a twelve month low of $3.86 and a twelve month high of $12.51.

Insider Activity at Evolus

In related news, insider Rui Avelar sold 29,996 shares of the company’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $4.89, for a total transaction of $146,680.44. Following the completion of the sale, the insider directly owned 430,542 shares of the company’s stock, valued at approximately $2,105,350.38. This represents a 6.51% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider David Moatazedi sold 116,720 shares of the company’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $4.89, for a total transaction of $570,760.80. Following the sale, the insider directly owned 618,369 shares of the company’s stock, valued at approximately $3,023,824.41. This represents a 15.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 163,504 shares of company stock worth $797,184. Corporate insiders own 5.90% of the company’s stock.

Institutional Investors Weigh In On Evolus

A number of hedge funds have recently bought and sold shares of EOLS. Seven Fleet Capital Management LP acquired a new stake in shares of Evolus in the fourth quarter valued at about $545,000. Alpine Global Management LLC acquired a new position in shares of Evolus during the 4th quarter worth about $173,000. Virtu Financial LLC bought a new stake in Evolus during the 4th quarter valued at approximately $151,000. Mercer Global Advisors Inc. ADV bought a new stake in Evolus during the 4th quarter valued at approximately $144,000. Finally, Wellington Management Group LLP grew its holdings in Evolus by 5.9% in the 4th quarter. Wellington Management Group LLP now owns 195,160 shares of the company’s stock valued at $1,298,000 after buying an additional 10,850 shares during the last quarter. 90.69% of the stock is currently owned by institutional investors.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.